Ruby Kapadia, DO
Addiction Medicine · Saddle Brook, NJNPI 1134544307
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,637 of the $4,770 with a category attached, or 76.2%. 28 manufacturers reported payments, led by Idorsia Pharmaceuticals US Inc at 24.7% of the total. Reporting peaked in 2022 at $1,325 and has fallen 55.7% since, to $587 in 2025. Among addiction medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 199 payments — averaging $23.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Idorsia Pharmaceuticals US Inc$1K
- AstraZeneca$738
- GSK$451
- AbbVie$408
- Braeburn Inc.$310
- Amgen$196
- plus $1K from 22 others
What the payments were for
- Speaking & faculty fees$99821%
- Food & beverage$3,63776%
- Education$1363%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Idorsia Pharmaceuticals US Inc | 6 | $1,176 |
| AstraZeneca | 34 | $738 |
| GSK | 23 | $451 |
| AbbVie | 13 | $408 |
| Braeburn Inc. | 30 | $310 |
| Amgen | 8 | $196 |
| Lilly USA, LLC | 12 | $182 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $173 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| Almatica Pharma LLC | 7 | $123 |
| Indivior Inc. | 7 | $108 |
| Tolmar, Inc. | 7 | $108 |
| Merck | 6 | $94 |
| Clarus Therapeutics Inc. | 8 | $84 |
| Pfizer | 4 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $63 |
| Lundbeck LLC | 2 | $58 |
| Novo Nordisk | 3 | $44 |
| Exact Sciences | 2 | $43 |
| Acerus Pharmaceuticals Corporation | 3 | $42 |
| Johnson & Johnson | 3 | $41 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Astellas Pharma US Inc | 2 | $31 |
| Antares Pharma, Inc. | 1 | $15 |
| Neuronetics, Inc. | 1 | $15 |
| Viiv Healthcare Company | 1 | $15 |
| Protega Pharmaceutials Inc | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,770 in reported general payments places this provider in the 95th percentile of 57 addiction medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 38 | $37,115 |
| MounjaroTirzepatide | 23 | $24,164 |
| EliquisApixaban | 19 | $17,404 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $14,243 |
| OzempicSemaglutide | 13 | $14,191 |
| Bydureon BciseExenatide Microspheres | 14 | $11,441 |
| Repatha SureclickEvolocumab | 19 | $10,476 |
| FarxigaDapagliflozin Propanediol | 13 | $6,856 |
| VascepaIcosapent Ethyl | 19 | $5,787 |
| MitigareColchicine | 12 | $2,712 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 57 | $1,464 |
| Lubiprostone | 12 | $1,287 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 53 | $1,033 |
| Rosuvastatin Calcium | 97 | $926 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 42 | $769 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $182 | $61,27961 claims |
| PfizerEliquis | $65 | $17,40419 claims |
| GSKTrelegy Ellipta | $451 | $14,24323 claims |
| Novo NordiskOzempic | $44 | $14,19113 claims |
| AstraZenecaFarxiga | $738 | $6,85613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 57 addiction medicine providers in New Jersey.
Other addiction medicine in Saddle Brook
- Joseph RanieriSewell$28K
- Peter KuponiyiEgg Harbor Township$8K
- Richard HellanderCamden$3K
- Hayman RambaranParamus$2K
- Mohammed RahmanNeptune$2K
- David RussoBridgeton$1K
- Sailakshmi RamanujamToms River$1K
- Usman IjazClifton$943
- Lance GoobermanMerchantville$847
- Nola MahoneyHamilton$648
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.